Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marjolein van Ballegooijen

Showing results (1-10 of 124) with videos related to

Pageof 13
Sort By:
Best Practice & Research. Clinical Gastroenterology|September 14, 2010
Simulation of colorectal cancer screening: what we do and do not know and does it matterMarjolein van Ballegooijen, Rob Boer, Ann G Zauber
BJOG : an International Journal of Obstetrics and Gynaecology|June 9, 2016
Authors' reply re: Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testingInge McM de Kok, Joost van Rosmalen, Marjolein van Ballegooijen
The American Journal of Gastroenterology|May 13, 2010
A decision-analytic evaluation of the cost-effectiveness of family history-based colorectal cancer screening programsScott D Ramsey, Janneke Wilschut, Rob Boer, et al.
International Journal of Cancer|November 30, 2006
Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the NetherlandsMatejka Rebolj, Marjolein van Ballegooijen, Louise-Maria Berkers, et al.
Diseases of the Colon and Rectum|September 18, 2010
United States Preventive Services Task Force recommendations: age to end screening misunderstoodAnn G Zauber, Marjolein van Ballegooijen, Diana Petitti, et al.
International Journal of Cancer|July 22, 2006
Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the NetherlandsAnita B Bos, Matejka Rebolj, J Dik F Habbema, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|August 29, 2012
Multicohort models in cost-effectiveness analysis: why aggregating estimates over multiple cohorts can hide useful informationJames F O'Mahony, Joost van Rosmalen, Ann G Zauber, et al.
European Journal of Cancer (Oxford, England : 1990)|August 18, 2009
Anxiety and borderline PAP smear resultsIda J Korfage, Marjolein van Ballegooijen, Hans Huveneers, et al.
Nederlands Tijdschrift Voor Geneeskunde|July 13, 2010
[Unequal discounting of health care costs and effects causes confusion]Marjolein van Ballegooijen, Inge M C M de Kok, J Dik F Habbema
Journal of the National Cancer Institute|July 3, 2009
Cost-effectiveness analysis of human papillomavirus vaccination in the NetherlandsInge M C M de Kok, Marjolein van Ballegooijen, J Dik F Habbema
Pageof 13

Showing results (1-10 of 124) with videos related to

Sort By:
Pageof 13
Best Practice & Research. Clinical Gastroenterology|September 14, 2010
Simulation of colorectal cancer screening: what we do and do not know and does it matterMarjolein van Ballegooijen, Rob Boer, Ann G Zauber
BJOG : an International Journal of Obstetrics and Gynaecology|June 9, 2016
Authors' reply re: Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testingInge McM de Kok, Joost van Rosmalen, Marjolein van Ballegooijen
The American Journal of Gastroenterology|May 13, 2010
A decision-analytic evaluation of the cost-effectiveness of family history-based colorectal cancer screening programsScott D Ramsey, Janneke Wilschut, Rob Boer, et al.
International Journal of Cancer|November 30, 2006
Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the NetherlandsMatejka Rebolj, Marjolein van Ballegooijen, Louise-Maria Berkers, et al.
Diseases of the Colon and Rectum|September 18, 2010
United States Preventive Services Task Force recommendations: age to end screening misunderstoodAnn G Zauber, Marjolein van Ballegooijen, Diana Petitti, et al.
International Journal of Cancer|July 22, 2006
Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the NetherlandsAnita B Bos, Matejka Rebolj, J Dik F Habbema, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|August 29, 2012
Multicohort models in cost-effectiveness analysis: why aggregating estimates over multiple cohorts can hide useful informationJames F O'Mahony, Joost van Rosmalen, Ann G Zauber, et al.
European Journal of Cancer (Oxford, England : 1990)|August 18, 2009
Anxiety and borderline PAP smear resultsIda J Korfage, Marjolein van Ballegooijen, Hans Huveneers, et al.
Nederlands Tijdschrift Voor Geneeskunde|July 13, 2010
[Unequal discounting of health care costs and effects causes confusion]Marjolein van Ballegooijen, Inge M C M de Kok, J Dik F Habbema
Journal of the National Cancer Institute|July 3, 2009
Cost-effectiveness analysis of human papillomavirus vaccination in the NetherlandsInge M C M de Kok, Marjolein van Ballegooijen, J Dik F Habbema
Pageof 13